Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186647 | 0.89 | BTK (0.81) | BTK | |
| SCHEMBL3223343 | 0.89 | BTK (0.81) | BTK | |
| SCHEMBL3210846 | 0.88 | BTK (0.79) | BTK | |
| SCHEMBL12850749 | 0.88 | BTK (0.79) | BTK | |
| SCHEMBL3210798 | 0.88 | BTK (0.78) | BTK | |
| SCHEMBL13186922 | 0.88 | BTK (0.78) | BTK | |
| SCHEMBL1728611 | 0.87 | BTK (0.77) | BTK | |
| SCHEMBL3221161 | 0.86 | BTK (0.76) | BTK | |
| SCHEMBL1725808 | 0.84 | BTK (0.72) | BTK | |
| SCHEMBL12799842 | 0.83 | BTK (0.71) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | claimed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | claimed |
| EP-2242749-B1 | NOVEL PYRIDINONES AND PYRIDAZINONES | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-7906509-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906509-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906509-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.